エラーカスケードは連続して発生します.

Same author

Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-Trial.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research·2026

Same author

Individualized management of primary hyperparathyroidism.

Journal of internal medicine·2026

Same author

Use of total calcium in hypoparathyroidism: a pragmatic approach but with limitations.

European journal of endocrinology·2025

Same author

EndoCompass Project: Research Roadmap for Calcium and Bone Endocrinology.

Hormone research in paediatrics·2025

Same author

Revised European Society of Endocrinology Clinical Practice Guideline: Treatment of Chronic Hypoparathyroidism in Adults.

European journal of endocrinology·2025

Same author

EndoCompass project: research roadmap for calcium and bone endocrinology.

European journal of endocrinology·2025

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

関連する実験動画

エラーカスケードは連続して発生します.

関連する概念動画

Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-Trial.

Individualized management of primary hyperparathyroidism.

Use of total calcium in hypoparathyroidism: a pragmatic approach but with limitations.

EndoCompass Project: Research Roadmap for Calcium and Bone Endocrinology.

Revised European Society of Endocrinology Clinical Practice Guideline: Treatment of Chronic Hypoparathyroidism in Adults.

EndoCompass project: research roadmap for calcium and bone endocrinology.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

関連する実験動画

エラーカスケードは連続して発生します.

関連する概念動画

関連記事

Sustained Improvement in Renal Function with Palopegteriparatide in Adults with Chronic Hypoparathyroidism: 2-Year Results from the Phase 3 PaTHway-Trial.

Individualized management of primary hyperparathyroidism.

Use of total calcium in hypoparathyroidism: a pragmatic approach but with limitations.

EndoCompass Project: Research Roadmap for Calcium and Bone Endocrinology.

Revised European Society of Endocrinology Clinical Practice Guideline: Treatment of Chronic Hypoparathyroidism in Adults.

EndoCompass project: research roadmap for calcium and bone endocrinology.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.